FTRE
Fortrea Holdings Inc.
$10.90
+$0.86(+8.57%)
50
Overall
60
Value
41
Tech
--
Quality
Market Cap
$1.03B
Volume
942.82K
52W Range
$3.97 - $25.05
Target Price
$10.95
Company Overview
| Mkt Cap | $1.03B | Price | $10.90 |
| Volume | 942.82K | Change | +8.57% |
| P/E Ratio | -3.1 | Open | $10.02 |
| Revenue | $2.7B | Prev Close | $10.04 |
| Net Income | $-328.5M | 52W Range | $3.97 - $25.05 |
| Div Yield | N/A | Target | $10.95 |
| Overall | 50 | Value | 60 |
| Quality | -- | Technical | 41 |
No chart data available
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Latest News
Truist Financial Keeps Their Hold Rating on Fortrea Holdings Inc. (FTRE)
TipRanks Auto-Generated Intelligence Newsdesk•17 days ago
Fortrea Holdings Inc. Navigates Growth and Challenges in Q3 Earnings Call
TipRanks Auto-Generated Newsdesk•17 days ago
Fortrea’s Givinostat Study: A New Hope for Young DMD Patients
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FTRE | $10.90 | +8.6% | 942.82K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |